Home Data Calendar Blog

AMRX

Tables

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Weighted Average Number Of Diluted Shares Outstanding		159.69	154.89	152.11	NA	151.39	150.99	149.89	NA	149.29	151.99	151.22	NA	147.56	147.39	147.96	NA	130.73	128.02	127.69	NA	128.22	NA	NA	NA	NA	NA	NA
Weighted Average Number Of Shares Outstanding Basic		154.22	153.74	152.11	NA	151.39	150.99	149.89	NA	149.29	149.00	148.01	NA	147.56	147.39	147.18	NA	130.73	128.02	127.69	NA	127.25	NA	NA	NA	NA	NA	NA
Earnings Per Share Basic		0.06	0.08	-0.05	-0.03	-0.02	-0.80	-0.01	-0.04	-0.03	0.10	0.05	-0.02	-0.06	-0.08	0.78	-0.23	-2.03	-0.13	-0.37	-0.07	0.05	-0.15	0.00	0.00	0.00	0.00	0.00
Earnings Per Share Diluted		0.06	0.08	-0.05	-0.03	-0.02	-0.80	-0.01	-0.04	-0.03	0.10	0.04	-0.02	-0.06	-0.08	0.78	-0.23	-2.03	-0.13	-0.37	-0.07	0.05	-0.15	0.00	0.00	0.00	0.00	0.00

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Revenue From Contract With Customer Excluding Assessed Tax		620.04	599.05	557.54	609.76	545.56	559.36	497.63	536.90	528.59	535.08	493.11	510.03	519.29	464.66	498.53	397.33	378.28	404.64	446.12	497.53	476.49	413.79	275.19	293.37	254.73	259.87	225.68
Revenues		620.04	599.05	557.54	609.76	545.56	559.36	497.63	536.90	528.59	535.08	493.11	510.03	519.29	464.66	498.53	397.33	378.28	404.64	446.12	497.53	476.49	413.79	275.19	293.37	254.73	259.87	225.68
Cost Of Goods And Services Sold		387.51	379.02	379.35	389.05	350.65	353.72	323.06	348.49	329.39	322.58	301.54	342.96	353.35	319.67	313.58	273.37	267.72	296.38	309.74	304.12	276.38	235.49	130.59	141.95	119.72	136.14	NA
Gross Profit		232.53	220.02	178.19	215.39	194.23	200.52	174.57	166.40	198.51	212.50	191.56	167.07	133.59	144.24	183.50	110.23	54.43	105.25	83.08	193.41	200.10	178.29	144.59	151.42	135.01	123.73	116.02
Research And Development Expense		41.38	37.80	38.69	41.91	50.23	50.75	52.80	51.87	48.93	52.86	48.18	53.46	44.52	45.57	36.38	48.05	38.12	48.02	53.86	56.65	43.00	50.34	44.21	43.49	41.32	47.18	NA
Selling General And Administrative Expense		113.01	105.57	102.10	102.16	100.07	98.81	98.67	97.22	91.40	86.16	90.73	84.69	83.12	80.94	77.98	74.08	63.80	67.28	84.44	74.24	78.08	53.00	25.12	26.97	27.44	26.94	NA
Operating Income Loss		75.65	80.08	34.45	36.03	44.35	-198.62	23.30	11.18	28.52	67.12	45.91	20.18	2.44	10.75	57.79	-23.14	-112.27	-18.91	-94.36	23.28	74.56	-181.06	63.55	79.02	78.75	44.60	NA
Interest Paid Net		47.90	47.64	41.07	50.51	34.89	30.03	27.29	30.07	30.24	31.52	29.92	30.98	30.77	33.05	35.39	36.70	40.77	41.07	40.03	42.43	38.68	31.55	18.84	17.12	17.68	NA	NA
Interest Income Expense Nonoperating Net		-50.91	-50.86	-49.31	-47.03	-42.39	-35.62	-33.34	-33.96	-34.40	-34.08	-33.88	-34.53	-34.90	-36.67	-39.90	-38.83	-42.21	-43.89	-43.28	-42.88	-43.02	-36.62	-21.05	-19.96	-19.22	-17.73	NA
Gains Losses On Extinguishment Of Debt		NA	NA	NA	0.00	0.00	0.30	NA	NA	NA	NA	NA	NA	NA	NA	NA	0.00	0.00	0.00	NA	0.00	0.00	-19.67	NA	-0.00	0.00	-2.53	NA
Income Tax Expense Benefit		-2.08	-0.02	0.67	-1.80	4.57	7.35	-3.46	4.14	4.05	2.65	0.36	1.49	0.14	2.19	-108.17	7.79	389.67	-5.70	-8.43	5.52	5.11	-12.42	0.36	-0.12	-0.74	1.90	NA
Income Taxes Paid Net		-3.49	0.50	3.42	-22.59	16.69	-11.13	4.39	-3.98	-16.19	3.88	0.73	-9.30	113.96	-1.09	-3.43	-1.60	3.32	-1.18	9.71	29.57	5.38	1.51	-1.51	1.76	4.02	NA	NA
Profit Loss		25.03	29.68	-10.09	-5.86	-2.39	-240.08	-6.46	-20.46	-6.09	32.18	14.54	-6.96	-22.03	-23.94	121.52	-64.90	-363.39	-50.53	-124.75	-20.33	17.46	-250.09	51.65	62.19	27.12	37.75	42.26
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax		-5.29	8.31	-14.27	-3.27	32.64	14.07	53.62	18.24	2.71	0.70	20.77	3.75	-1.60	-9.77	-62.66	NA	NA	0.00	0.00	NA	NA	NA	NA	NA	NA	NA	NA
Net Income Loss		15.54	22.23	-15.63	-12.03	-7.61	-242.13	-8.82	-21.80	-7.78	29.99	12.75	-3.04	-8.97	-12.00	115.07	-32.13	-265.01	-16.90	-47.88	-8.77	6.89	-17.86	NA	0.00	0.00	0.00	NA
Comprehensive Income Net Of Tax		5.46	16.23	-13.18	-6.93	8.98	-119.59	22.43	2.03	-3.47	14.97	13.81	-3.04	-10.57	-18.27	81.73	-26.85	-262.82	-19.55	-44.20	-6.63	3.57	-20.27	0.00	0.00	0.00	0.00	NA
Net Income Loss Available To Common Stockholders Basic		9.68	11.92	-6.94	-4.33	-2.69	-120.81	-2.16	-6.38	-4.24	14.53	6.71	-3.04	-8.97	-12.00	115.07	-32.13	-265.01	-16.90	-47.88	-8.77	6.95	-19.10	0.00	0.00	0.00	0.00	0.00

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Assets		3687.08	3700.89	3626.61	3799.34	3874.04	4041.41	3888.97	3939.66	3974.41	4023.05	3960.07	4006.03	4037.54	4056.76	4390.80	3665.89	3703.94	4262.14	4384.59	4352.74	4582.05	4544.59	0.00	0.00	NA	NA	NA
Liabilities And Stockholders Equity		3687.08	3700.89	3626.61	3799.34	3874.04	4041.41	3888.97	3939.66	3974.41	4023.05	3960.07	4006.03	4037.54	4056.76	4390.80	3665.89	3703.94	4262.14	4384.59	4352.74	4582.05	4544.59	0.00	0.00	NA	NA	NA
Stockholders Equity		330.86	318.17	294.41	298.42	297.47	280.33	391.12	360.34	350.51	346.11	323.01	303.27	301.04	306.00	318.38	232.01	218.00	459.66	472.20	504.75	NA	NA	0.00	0.00	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Assets Current		1456.08	1421.79	1307.33	1411.82	1419.83	1553.60	1389.68	1520.11	1570.34	1563.47	1559.66	1551.54	1543.72	1480.87	1773.70	1210.21	1205.83	1185.85	1267.97	1286.64	1431.30	1347.89	0.00	0.00	NA	NA	NA
Cash And Cash Equivalents At Carrying Value		86.93	109.28	144.67	25.98	87.33	91.98	210.48	247.79	302.65	278.31	452.10	341.38	281.28	266.14	405.24	151.20	212.74	54.89	63.95	213.39	165.19	61.52	0.00	0.00	19.35	48.22	NA
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents		95.61	114.58	151.07	35.23	95.89	98.18	216.54	256.74	310.62	283.15	455.81	347.12	283.65	268.27	406.93	152.82	217.06	57.02	66.74	218.78	172.19	68.59	52.62	77.92	21.35	51.84	NA
Accounts Receivable Net Current		NA	NA	545.76	741.79	628.74	688.85	538.31	662.58	627.95	652.01	530.60	638.89	707.10	582.73	722.68	604.39	518.11	634.67	640.21	481.50	641.03	626.49	NA	351.37	NA	NA	NA
Inventory Net		576.47	550.56	529.04	530.74	543.86	533.03	512.24	489.39	520.25	523.38	497.01	490.65	475.76	443.96	437.96	381.07	401.83	414.63	448.29	457.22	490.77	512.48	NA	284.04	NA	NA	NA
Prepaid Expense And Other Assets Current		91.44	81.76	81.42	103.56	149.65	232.20	121.41	110.22	110.21	103.80	75.14	73.47	76.26	184.75	204.41	70.16	66.70	77.06	111.56	128.32	126.39	139.60	NA	42.40	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Property Plant And Equipment Gross		NA	NA	NA	915.79	NA	NA	NA	908.72	NA	NA	NA	809.89	NA	NA	NA	754.04	NA	NA	NA	753.58	760.57	748.79	NA	643.13	NA	NA	NA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment		NA	NA	NA	445.97	NA	NA	NA	394.56	NA	NA	NA	332.14	NA	NA	NA	276.05	NA	NA	NA	209.44	193.07	179.46	NA	156.37	NA	NA	NA
Amortization Of Intangible Assets		40.60	40.80	41.10	44.62	44.55	41.98	40.92	43.70	43.81	43.52	41.67	43.87	44.55	43.98	42.58	40.18	38.02	34.80	30.96	28.88	25.66	16.69	1.76	0.92	1.28	0.89	NA
Property Plant And Equipment Net		451.85	459.11	462.61	469.81	470.15	483.62	500.91	514.16	459.65	468.42	471.17	477.75	462.44	460.53	467.56	478.00	490.71	508.09	514.41	544.15	567.50	569.33	NA	486.76	NA	NA	NA
Goodwill		598.63	599.21	599.16	598.85	599.50	600.97	602.89	593.02	566.41	549.09	522.76	522.81	522.69	527.48	514.73	419.50	419.67	420.02	421.64	426.23	410.62	386.48	NA	26.44	NA	NA	NA
Indefinite Lived Intangible Assets Excluding Goodwill		387.86	390.36	390.36	390.75	405.43	405.43	405.43	405.43	405.52	422.99	379.39	379.39	381.12	381.12	381.12	382.07	382.52	428.78	429.14	451.93	565.87	571.25	NA	1.15	NA	NA	NA
Intangible Assets Net Excluding Goodwill		982.53	1015.38	1055.32	1096.09	1159.01	1204.22	1209.82	1166.92	1232.73	1293.33	1262.95	1304.63	1349.11	1423.83	1475.16	1382.75	1435.80	1553.33	1591.16	1654.97	1733.02	1788.53	NA	44.60	NA	NA	NA
Finite Lived Intangible Assets Net		594.68	625.02	664.96	705.34	753.58	798.80	804.39	761.50	827.20	870.34	883.56	925.23	968.00	1042.71	1094.05	1000.68	1053.28	1124.55	1162.02	1203.04	1167.15	1217.28	NA	43.45	NA	NA	NA
Other Assets Noncurrent		89.04	93.24	86.43	103.22	108.26	79.84	63.94	20.61	19.53	19.22	19.56	31.89	31.14	28.73	26.46	44.27	18.61	63.46	62.42	67.59	73.64	78.65	NA	11.26	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Liabilities Current		760.60	777.35	703.71	752.80	818.00	993.06	602.04	677.24	667.34	672.86	636.78	676.90	667.89	655.02	965.07	550.41	534.91	546.16	599.53	553.85	749.27	669.74	0.00	0.00	NA	NA	NA
Long Term Debt Current		30.53	30.41	29.96	29.96	29.94	29.92	30.52	30.61	30.47	30.46	29.82	44.23	29.78	29.76	29.74	21.48	NA	NA	NA	21.45	NA	NA	NA	89.17	NA	NA	NA
Accounts Payable Current		177.40	139.53	136.92	165.98	NA	NA	NA	131.08	NA	NA	NA	153.14	NA	NA	NA	103.02	NA	NA	NA	114.85	124.54	169.05	NA	70.01	NA	NA	NA
Accounts Payable And Accrued Liabilities Current		NA	NA	467.42	538.20	531.46	561.69	539.73	583.35	589.41	596.23	574.32	613.66	613.62	599.49	606.92	507.48	495.86	505.14	558.75	514.44	513.12	555.63	NA	194.78	NA	NA	NA
Other Accrued Liabilities Current		55.45	44.47	44.45	45.81	NA	NA	NA	40.88	NA	NA	NA	46.93	NA	NA	NA	35.90	NA	NA	NA	37.35	30.50	35.18	NA	23.82	NA	NA	NA
Taxes Payable Current		NA	NA	1.07	0.36	NA	NA	NA	2.52	NA	NA	NA	5.54	NA	NA	NA	8.73	NA	NA	NA	1.16	NA	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Liabilities Noncurrent		2735.10	2740.66	2760.70	2837.61	2839.38	2857.47	2863.10	2878.54	2908.65	2945.81	2943.50	2972.39	3009.52	3018.34	3009.71	2768.70	2773.31	2966.63	2985.28	2902.52	2917.46	2923.51	NA	1420.59	NA	NA	NA
Long Term Debt		2572.35	2579.58	2591.69	2621.94	2637.16	2652.37	NA	2710.67	NA	NA	NA	2779.49	2786.91	2794.33	2801.76	2630.53	NA	NA	NA	2652.05	NA	2662.73	NA	1444.44	NA	NA	NA
Long Term Debt Noncurrent		2541.81	2549.18	2561.72	2591.98	2607.22	2622.45	2672.66	2680.05	2687.67	2720.12	2728.21	2735.26	2757.14	2764.58	2772.03	2609.05	2614.41	2619.79	2625.15	2630.60	NA	2641.30	NA	1355.27	NA	NA	NA
Minority Interest		-176.62	-167.40	-159.75	-114.44	-103.18	-107.34	16.28	6.63	32.66	44.16	43.69	41.66	47.16	65.02	85.08	114.78	177.72	289.70	327.58	391.61	NA	NA	NA	NA	NA	NA	NA
Other Liabilities Noncurrent		NA	NA	41.46	87.47	78.26	79.21	32.87	38.90	60.80	63.26	63.79	85.68	96.19	93.77	80.85	39.58	38.53	28.65	37.72	38.78	44.77	45.67	NA	7.79	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Stockholders Equity		330.86	318.17	294.41	298.42	297.47	280.33	391.12	360.34	350.51	346.11	323.01	303.27	301.04	306.00	318.38	232.01	218.00	459.66	472.20	504.75	NA	NA	0.00	0.00	NA	NA	NA
Stockholders Equity Including Portion Attributable To Noncontrolling Interest		154.24	150.77	134.67	183.98	194.29	172.99	407.41	366.97	383.17	390.27	366.71	344.93	348.20	371.02	403.46	346.79	395.72	749.35	799.78	896.36	915.32	939.49	NA	0.00	NA	NA	NA
Additional Paid In Capital		715.45	708.23	700.72	691.63	683.75	675.59	666.80	658.35	650.54	642.66	634.48	628.41	623.13	617.50	611.60	606.97	565.64	544.16	537.16	530.44	520.16	517.12	NA	8.56	NA	NA	NA
Retained Earnings Accumulated Deficit		-391.53	-401.21	-413.13	-406.18	-401.85	-399.16	-278.35	-276.20	-269.82	-265.58	-280.12	-286.82	-283.78	-274.81	-262.81	-377.88	-345.75	-80.75	-63.84	-20.92	-12.15	-19.10	NA	-382.79	NA	NA	NA
Accumulated Other Comprehensive Income Loss Net Of Tax		3.87	8.08	3.76	9.94	12.54	0.87	-0.35	-24.83	-33.23	-33.98	-34.36	-41.32	-41.31	-39.70	-33.41	-0.07	-4.88	-6.75	-4.10	-7.75	-9.89	-6.50	NA	-14.23	NA	NA	NA
Minority Interest		-176.62	-167.40	-159.75	-114.44	-103.18	-107.34	16.28	6.63	32.66	44.16	43.69	41.66	47.16	65.02	85.08	114.78	177.72	289.70	327.58	391.61	NA	NA	NA	NA	NA	NA	NA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value		6.69	6.56	7.60	7.83	7.69	8.26	8.06	7.74	7.71	7.63	5.33	5.13	5.42	5.66	4.54	5.01	6.09	6.22	4.35	3.61	3.59	1.64	NA	NA	NA	NA	NA
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders		10.64	21.20	26.81	0.80	2.50	2.90	4.40	19.00	9.00	17.00	9.00	2.00	0.00	1.00	0.00	-0.10	0.10	0.00	0.00	13.50	35.50	NA	NA	NA	NA	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Net Cash Provided By Used In Operating Activities		81.39	-11.35	139.71	-23.29	93.57	-125.52	120.34	63.26	82.36	-51.93	148.13	105.96	44.78	179.24	49.03	-50.89	139.91	21.09	-108.41	259.65	62.13	-98.58	27.03	65.27	73.51	NA	NA
Net Cash Provided By Used In Investing Activities		-13.48	-12.28	-11.74	-11.47	-49.33	-16.12	-97.39	-86.97	-11.63	-82.89	-12.69	-31.80	-14.78	-8.93	-262.04	-4.77	29.98	-23.33	-21.47	5.32	-40.77	-341.43	-19.50	-8.90	-35.04	NA	NA
Net Cash Provided By Used In Financing Activities		-86.58	-12.26	-12.90	-22.17	-46.13	23.25	-61.57	-30.35	-43.55	-38.07	-26.15	-11.28	-14.81	-310.08	467.98	-7.30	-7.60	-9.07	-21.86	-218.92	82.60	457.24	-33.25	0.50	-63.77	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Net Cash Provided By Used In Operating Activities		81.39	-11.35	139.71	-23.29	93.57	-125.52	120.34	63.26	82.36	-51.93	148.13	105.96	44.78	179.24	49.03	-50.89	139.91	21.09	-108.41	259.65	62.13	-98.58	27.03	65.27	73.51	NA	NA
Net Income Loss		15.54	22.23	-15.63	-12.03	-7.61	-242.13	-8.82	-21.80	-7.78	29.99	12.75	-3.04	-8.97	-12.00	115.07	-32.13	-265.01	-16.90	-47.88	-8.77	6.89	-17.86	NA	0.00	0.00	0.00	NA
Profit Loss		25.03	29.68	-10.09	-5.86	-2.39	-240.08	-6.46	-20.46	-6.09	32.18	14.54	-6.96	-22.03	-23.94	121.52	-64.90	-363.39	-50.53	-124.75	-20.33	17.46	-250.09	51.65	62.19	27.12	37.75	42.26
Increase Decrease In Accounts Receivable		17.92	128.99	-195.97	113.29	-60.13	150.83	-124.27	34.52	-24.06	121.55	-108.39	-67.53	126.52	-136.66	60.89	86.27	-116.50	-2.06	165.01	-163.79	14.66	65.03	-4.98	13.21	-20.40	NA	NA
Increase Decrease In Inventories		42.57	38.02	22.51	11.07	25.93	39.85	25.55	-16.63	11.06	34.30	20.28	33.06	47.54	30.40	2.78	-5.51	6.25	5.48	14.18	-10.83	-17.95	24.07	47.59	6.64	14.30	NA	NA
Share Based Compensation		6.69	6.56	7.60	7.83	7.69	8.26	8.06	7.74	7.71	7.63	5.33	5.13	5.42	5.66	4.54	5.01	6.09	6.22	4.35	3.61	3.59	160.40	0.00	0.00	0.00	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Net Cash Provided By Used In Investing Activities		-13.48	-12.28	-11.74	-11.47	-49.33	-16.12	-97.39	-86.97	-11.63	-82.89	-12.69	-31.80	-14.78	-8.93	-262.04	-4.77	29.98	-23.33	-21.47	5.32	-40.77	-341.43	-19.50	-8.90	-35.04	NA	NA
Payments To Acquire Property Plant And Equipment		11.66	12.00	9.69	11.47	19.10	5.05	10.79	17.50	10.64	7.81	11.78	29.53	10.99	8.55	7.37	4.52	13.04	11.64	17.99	20.02	26.46	17.10	19.50	24.62	15.54	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Net Cash Provided By Used In Financing Activities		-86.58	-12.26	-12.90	-22.17	-46.13	23.25	-61.57	-30.35	-43.55	-38.07	-26.15	-11.28	-14.81	-310.08	467.98	-7.30	-7.60	-9.07	-21.86	-218.92	82.60	457.24	-33.25	0.50	-63.77	NA	NA

		2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31
Revenues		620.04	599.05	557.54	609.76	545.56	559.36	497.63	536.90	528.59	535.08	493.11	510.03	519.29	464.66	498.53	397.33	378.28	404.64	446.12	497.53	476.49	413.79	275.19	293.37	254.73	259.87	225.68
Saol Baclofen Franchise Acquisition		NA	NA	NA	4.90	5.60	6.30	2.90	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Operating, Amneal Specialty Pharma		97.30	96.99	91.68	102.55	89.48	97.00	85.09	101.01	92.75	88.64	95.93	85.47	87.87	94.26	87.98	97.05	87.26	69.58	63.64	86.63	85.31	52.02	0.00	NA	0.00	NA	NA
Operating, Av K A R E		131.88	128.35	122.06	108.04	105.81	97.46	94.80	89.62	88.72	86.00	84.67	82.42	89.51	63.85	57.97	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Operating, Generics		390.86	373.70	343.81	399.17	350.27	364.89	317.75	346.27	347.13	360.44	312.51	342.14	341.92	306.56	352.59	300.28	291.02	335.06	382.48	410.90	391.18	361.77	275.19	NA	NA	NA	NA
Anti Infective,US, Generics		7.38	6.09	5.17	6.42	4.96	5.57	6.25	5.50	9.41	9.68	5.91	7.79	9.81	9.72	13.25	12.32	9.91	8.15	5.94	NA	NA	NA	NA	NA	NA	NA	NA
Antiviral,US, Generics		7.15	3.60	25.47	22.95	5.78	1.30	10.57	3.27	9.76	-0.26	-7.94	-0.29	9.24	0.95	15.82	8.11	3.57	1.35	14.46	NA	NA	NA	NA	NA	NA	NA	NA
Cardiovascular System,US, Generics		32.46	33.15	32.50	33.76	28.93	32.04	23.45	34.73	35.69	36.13	35.31	31.35	28.52	25.11	29.68	23.47	26.24	31.14	36.22	NA	NA	NA	NA	NA	NA	NA	NA
Central Nervous System,US, Generics		96.59	83.60	84.58	106.49	96.88	108.79	81.12	86.93	91.26	106.63	96.29	119.46	107.14	96.23	101.58	87.42	93.82	117.40	124.78	NA	NA	NA	NA	NA	NA	NA	NA
Central Nervous System,US, Specialty		61.14	59.56	60.14	70.35	61.78	65.36	58.17	75.49	68.87	65.13	67.71	75.31	68.06	74.06	68.31	74.81	67.45	50.69	42.90	NA	NA	NA	NA	NA	NA	NA	NA
Dermatology,US, Generics		17.28	17.95	18.00	17.81	17.33	17.94	13.48	12.92	14.86	14.82	12.88	15.77	14.82	10.44	15.24	16.68	15.77	14.77	12.97	NA	NA	NA	NA	NA	NA	NA	NA
Gastroenterology,US, Generics		18.86	19.91	14.36	19.52	17.13	17.53	16.62	20.16	17.17	19.70	19.46	18.92	21.37	16.62	23.54	14.21	9.08	9.94	9.56	NA	NA	NA	NA	NA	NA	NA	NA
Gastroenterology,US, Specialty		NA	NA	NA	NA	NA	0.48	0.07	NA	NA	NA	NA	-0.14	1.25	0.44	0.05	2.88	0.41	0.45	0.48	NA	NA	NA	NA	NA	NA	NA	NA
Government Label,US, Av K A R E		32.76	29.87	24.52	25.50	26.00	22.28	24.46	28.24	29.90	29.17	31.07	28.70	28.90	25.07	21.38	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Hormonal Allergy,US, Generics		126.42	126.44	104.85	110.51	119.73	118.31	96.37	101.11	107.61	111.65	106.70	84.08	93.58	89.28	87.48	84.39	85.25	92.29	102.72	NA	NA	NA	NA	NA	NA	NA	NA
Hormonal Allergy,US, Specialty		28.49	29.01	24.76	25.71	22.01	24.32	19.42	19.17	16.42	16.01	16.80	13.97	13.04	13.67	13.95	13.24	11.52	9.89	10.90	NA	NA	NA	NA	NA	NA	NA	NA
Institutional,US, Av K A R E		10.55	8.98	8.86	7.07	8.30	6.06	6.32	6.34	7.87	5.78	5.18	5.73	4.89	4.51	3.41	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Metabolic Disease Endocrine,US, Generics		11.03	14.94	9.27	10.63	9.28	9.99	11.23	12.13	12.89	6.88	6.56	11.61	9.99	6.77	17.23	14.48	12.57	10.89	17.85	NA	NA	NA	NA	NA	NA	NA	NA
Oncology,US, Generics		37.72	28.55	10.58	16.41	12.24	18.42	17.21	29.64	21.20	33.45	19.03	15.76	13.93	16.57	15.97	9.74	16.27	21.75	14.96	NA	NA	NA	NA	NA	NA	NA	NA
Other Therapeutic Classes,US, Generics		27.27	27.81	25.89	31.78	29.10	22.33	35.36	30.07	18.98	11.14	9.73	28.13	22.66	26.67	21.75	NA	10.13	15.26	18.18	NA	NA	NA	NA	NA	NA	NA	NA
Other Therapeutic Classes,US, Specialty		7.67	8.42	6.78	6.49	5.69	6.84	7.43	6.36	7.45	7.49	11.42	-1.71	5.63	5.89	5.39	NA	7.76	8.46	8.82	NA	NA	NA	NA	NA	NA	NA	NA
Respiratory,US, Generics		7.83	11.14	12.81	14.58	8.72	12.12	5.67	9.09	8.23	10.46	8.18	9.19	10.88	7.24	10.07	9.51	7.77	8.42	9.22	NA	NA	NA	NA	NA	NA	NA	NA
Distribution Service,US, Av K A R E		81.90	83.80	83.23	70.00	66.06	64.24	60.26	51.06	48.05	48.32	45.50	44.85	53.40	31.84	31.59	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Product And Service Other,US, Av K A R E		6.66	5.70	5.45	5.48	5.45	4.88	3.76	3.98	2.90	2.73	2.92	3.14	2.31	2.42	1.59	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Av K A R E		131.88	128.35	122.06	108.04	105.81	97.46	94.80	89.62	88.72	86.00	84.67	82.42	89.51	63.85	57.97	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Generics		390.86	373.70	343.81	399.17	350.27	364.89	317.75	346.27	347.13	360.44	312.51	342.14	341.92	306.56	352.59	300.28	291.02	335.06	382.48	NA	NA	NA	NA	NA	NA	NA	NA
Specialty		97.30	96.99	91.68	102.55	89.48	97.00	85.09	101.01	92.75	88.64	95.93	85.47	87.87	94.26	87.98	97.05	87.26	69.58	63.64	NA	NA	NA	NA	NA	NA	NA	NA
Non Us, Generics		0.87	0.55	0.30	0.27	0.20	0.57	0.42	0.71	0.05	0.15	0.40	0.39	0.00	0.96	0.98	0.61	0.64	3.72	15.63	NA	NA	NA	NA	NA	NA	NA	NA
Revenue From Contract With Customer Excluding Assessed Tax		620.04	599.05	557.54	609.76	545.56	559.36	497.63	536.90	528.59	535.08	493.11	510.03	519.29	464.66	498.53	397.33	378.28	404.64	446.12	497.53	476.49	413.79	275.19	293.37	254.73	259.87	225.68
Saol Baclofen Franchise Acquisition		NA	NA	NA	4.90	5.60	6.30	2.90	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Operating, Amneal Specialty Pharma		97.30	96.99	91.68	102.55	89.48	97.00	85.09	101.01	92.75	88.64	95.93	85.47	87.87	94.26	87.98	97.05	87.26	69.58	63.64	86.63	85.31	52.02	0.00	NA	0.00	NA	NA
Operating, Av K A R E		131.88	128.35	122.06	108.04	105.81	97.46	94.80	89.62	88.72	86.00	84.67	82.42	89.51	63.85	57.97	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Operating, Generics		390.86	373.70	343.81	399.17	350.27	364.89	317.75	346.27	347.13	360.44	312.51	342.14	341.92	306.56	352.59	300.28	291.02	335.06	382.48	410.90	391.18	361.77	275.19	NA	NA	NA	NA
Anti Infective,US, Generics		7.38	6.09	5.17	6.42	4.96	5.57	6.25	5.50	9.41	9.68	5.91	7.79	9.81	9.72	13.25	12.32	9.91	8.15	5.94	NA	NA	NA	NA	NA	NA	NA	NA
Antiviral,US, Generics		7.15	3.60	25.47	22.95	5.78	1.30	10.57	3.27	9.76	-0.26	-7.94	-0.29	9.24	0.95	15.82	8.11	3.57	1.35	14.46	NA	NA	NA	NA	NA	NA	NA	NA
Cardiovascular System,US, Generics		32.46	33.15	32.50	33.76	28.93	32.04	23.45	34.73	35.69	36.13	35.31	31.35	28.52	25.11	29.68	23.47	26.24	31.14	36.22	NA	NA	NA	NA	NA	NA	NA	NA
Central Nervous System,US, Generics		96.59	83.60	84.58	106.49	96.88	108.79	81.12	86.93	91.26	106.63	96.29	119.46	107.14	96.23	101.58	87.42	93.82	117.40	124.78	NA	NA	NA	NA	NA	NA	NA	NA
Central Nervous System,US, Specialty		61.14	59.56	60.14	70.35	61.78	65.36	58.17	75.49	68.87	65.13	67.71	75.31	68.06	74.06	68.31	74.81	67.45	50.69	42.90	NA	NA	NA	NA	NA	NA	NA	NA
Dermatology,US, Generics		17.28	17.95	18.00	17.81	17.33	17.94	13.48	12.92	14.86	14.82	12.88	15.77	14.82	10.44	15.24	16.68	15.77	14.77	12.97	NA	NA	NA	NA	NA	NA	NA	NA
Gastroenterology,US, Generics		18.86	19.91	14.36	19.52	17.13	17.53	16.62	20.16	17.17	19.70	19.46	18.92	21.37	16.62	23.54	14.21	9.08	9.94	9.56	NA	NA	NA	NA	NA	NA	NA	NA
Gastroenterology,US, Specialty		NA	NA	NA	NA	NA	0.48	0.07	NA	NA	NA	NA	-0.14	1.25	0.44	0.05	2.88	0.41	0.45	0.48	NA	NA	NA	NA	NA	NA	NA	NA
Government Label,US, Av K A R E		32.76	29.87	24.52	25.50	26.00	22.28	24.46	28.24	29.90	29.17	31.07	28.70	28.90	25.07	21.38	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Hormonal Allergy,US, Generics		126.42	126.44	104.85	110.51	119.73	118.31	96.37	101.11	107.61	111.65	106.70	84.08	93.58	89.28	87.48	84.39	85.25	92.29	102.72	NA	NA	NA	NA	NA	NA	NA	NA
Hormonal Allergy,US, Specialty		28.49	29.01	24.76	25.71	22.01	24.32	19.42	19.17	16.42	16.01	16.80	13.97	13.04	13.67	13.95	13.24	11.52	9.89	10.90	NA	NA	NA	NA	NA	NA	NA	NA
Institutional,US, Av K A R E		10.55	8.98	8.86	7.07	8.30	6.06	6.32	6.34	7.87	5.78	5.18	5.73	4.89	4.51	3.41	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Metabolic Disease Endocrine,US, Generics		11.03	14.94	9.27	10.63	9.28	9.99	11.23	12.13	12.89	6.88	6.56	11.61	9.99	6.77	17.23	14.48	12.57	10.89	17.85	NA	NA	NA	NA	NA	NA	NA	NA
Oncology,US, Generics		37.72	28.55	10.58	16.41	12.24	18.42	17.21	29.64	21.20	33.45	19.03	15.76	13.93	16.57	15.97	9.74	16.27	21.75	14.96	NA	NA	NA	NA	NA	NA	NA	NA
Other Therapeutic Classes,US, Generics		27.27	27.81	25.89	31.78	29.10	22.33	35.36	30.07	18.98	11.14	9.73	28.13	22.66	26.67	21.75	NA	10.13	15.26	18.18	NA	NA	NA	NA	NA	NA	NA	NA
Other Therapeutic Classes,US, Specialty		7.67	8.42	6.78	6.49	5.69	6.84	7.43	6.36	7.45	7.49	11.42	-1.71	5.63	5.89	5.39	NA	7.76	8.46	8.82	NA	NA	NA	NA	NA	NA	NA	NA
Respiratory,US, Generics		7.83	11.14	12.81	14.58	8.72	12.12	5.67	9.09	8.23	10.46	8.18	9.19	10.88	7.24	10.07	9.51	7.77	8.42	9.22	NA	NA	NA	NA	NA	NA	NA	NA
Distribution Service,US, Av K A R E		81.90	83.80	83.23	70.00	66.06	64.24	60.26	51.06	48.05	48.32	45.50	44.85	53.40	31.84	31.59	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Product And Service Other,US, Av K A R E		6.66	5.70	5.45	5.48	5.45	4.88	3.76	3.98	2.90	2.73	2.92	3.14	2.31	2.42	1.59	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Av K A R E		131.88	128.35	122.06	108.04	105.81	97.46	94.80	89.62	88.72	86.00	84.67	82.42	89.51	63.85	57.97	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Generics		390.86	373.70	343.81	399.17	350.27	364.89	317.75	346.27	347.13	360.44	312.51	342.14	341.92	306.56	352.59	300.28	291.02	335.06	382.48	NA	NA	NA	NA	NA	NA	NA	NA
Specialty		97.30	96.99	91.68	102.55	89.48	97.00	85.09	101.01	92.75	88.64	95.93	85.47	87.87	94.26	87.98	97.05	87.26	69.58	63.64	NA	NA	NA	NA	NA	NA	NA	NA
Non Us, Generics		0.87	0.55	0.30	0.27	0.20	0.57	0.42	0.71	0.05	0.15	0.40	0.39	0.00	0.96	0.98	0.61	0.64	3.72	15.63	NA	NA	NA	NA	NA	NA	NA	NA

Plots across concepts

Line plots across dimensions of each concept